Incorporating Neurokinin-Targeted Therapies Into Patient Care Plans
January 28th 2025A panelist discusses how she proactively addresses safety concerns about neurokinin-targeted therapies through evidence-based patient education and systematic monitoring while implementing streamlined protocols and documentation systems to effectively integrate these treatments into clinical workflow.
Watch
Evaluating Neurokinin-Targeted Therapies for Vasomotor Symptoms (VMS)
January 21st 2025A panelist discusses how she carefully transitions patients to neurokinin-targeted therapies by establishing realistic timelines for symptom improvement and actively monitoring patient response while providing education about potential benefits and limitations of the new treatment approach.
Watch
Exploring Key Management Decisions for Patients Experiencing VMS
January 21st 2025Kamilia Smith, MD, FACOG, NCMP, discusses how vasomotor symptoms (VMS) significantly impact sleep quality while examining the evolving landscape of VMS management, including both current treatment effects on sleep and promising future therapeutic developments.
Watch
Key Unmet Needs in IPF and PPF
January 17th 2025Anna Podolanczuk, M.D., M.S., discusses the key unmet needs in diagnosing idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), and how artificial intelligence (AI) could play a transformative role in enabling earlier detection of these diseases in the future.
Watch
Incorporating Patient Characteristics Into Treatment Decisions for VMS
January 14th 2025Kamilia Smith, MD, FACOG, NCMP, discusses how patient selection for novel treatments such as fezolinetant and elinzanetant must consider individual clinical characteristics, while also recognizing the unique ways that women of color may experience menopausal symptoms and barriers to care.
Watch
The Role of Biomarkers and Biopsy for IPF and PPF
January 10th 2025Anna Podolanczuk, M.D., M.S., discusses how biomarker testing plays a role in diagnosing idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), helping to distinguish these diseases from other respiratory conditions, as well as the role of biopsy and the histopathological features commonly seen in these diseases.
Watch
Shared Decision-Making with Neurokinin-Targeted Therapies for VMS
January 7th 2025Kamilia Smith, MD, FACOG, NCMP, discusses how shared decision-making approaches combined with emerging neurokinin-targeted therapies offer promising solutions to improve treatment adherence and overcome historical barriers in managing vasomotor symptoms (VMS).
Watch
Diagnosing PPF and the Importance of Early Detection
January 3rd 2025Anna-Maria Hoffmann-Vold, M.D., Ph.D., discusses how progressive pulmonary fibrosis is diagnosed in clinical practice, the barriers hindering early diagnosis, strategies to overcome these challenges and the critical role of early detection and intervention in improving patient outcomes and reducing long-term healthcare costs.
Watch
Best Practices in Diagnosis of IPF and PPF
January 3rd 2025Anna Podolanczuk, M.D., M.S., discusses how the differential diagnosis for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) is approached, the importance of early diagnosis and why these diseases are often misdiagnosed.
Watch
Patient Education About VMS and Associated Therapies
December 31st 2024Kamilia Smith, MD, FACOG, NCMP, discusses how educating patients about the serious long-term health risks of untreated vasomotor symptoms (VMS) requires a comprehensive strategy that includes clear communication about cardiovascular and cognitive consequences, alongside practical steps to improve treatment adoption and adherence.
Watch
Epidemiology and Economic Burden of IPF and PPF
December 27th 2024Anna Podolanczuk, M.D., M.S., discusses how key epidemiological trends in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), including changes in incidence and prevalence, contribute to the growing economic burden that patients with these conditions face.
Watch
Evaluating Patient Attitudes Toward Conventional VMS Therapies
December 24th 2024Kamilia Smith, MD, FACOG, NCMP, discusses how societal stigma and cultural misconceptions about menopause, combined with widespread misinformation about treatment options, create significant barriers that discourage women from seeking appropriate medical care for menopausal symptoms.
Watch
PPF Symptoms and Impact on Quality of Life
December 17th 2024Anna-Maria Hoffmann-Vold, M.D., Ph.D., discusses the most common symptoms of progressive pulmonary fibrosis (PPF), how they typically evolve and the impact of PPF on patients’ daily activities and quality of life as the disease progresses.
Watch
Important Clinical Considerations for Patients Experiencing Vasomotor Symptoms (VMS)
December 17th 2024Kamilia Smith, MD, FACOG, NCMP, discusses how identifying and effectively treating vasomotor symptoms (VMS) in menopausal women are hindered by diagnostic challenges, inadequate screening practices, and patient barriers including stigma, lack of awareness, and concerns about treatment options.
Watch
Empowering Vitiligo Patients Through Education and Digital Health Solutions for Long-Term Management
December 16th 2024Seemal Desai, M.D., FAAD, discusses how effective patient education and engagement strategies, combined with emerging telemedicine and digital health technologies, enhance vitiligo care delivery, disease monitoring and patient self-management capabilities.
Watch
Distinguishing Between the Different Interstitial Lung Diseases
December 13th 2024Anna Podolanczuk, M.D., M.S., discusses how different types of interstitial lung diseases and their main risk factors contribute to the development of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), as well as how these diseases present with common symptoms and progress over time.
Watch
Addressing the Psychosocial Impact of Vitiligo: Enhancing Patient Support and Treatment Adherence
December 9th 2024The panelist discusses how vitiligo’s psychological and social impacts significantly affect patients’ quality of life and treatment adherence, necessitating a holistic approach that addresses both physical symptoms and psychosocial support needs.
Watch
Optimizing Access in Vitiligo Treatment: Managed Care Strategies for New Therapies
December 2nd 2024Seemal Desai, M.D., FAAD, discusses how managed care organizations can improve access to advanced vitiligo treatments through updated formulary decisions and treatment algorithms while addressing insurance coverage barriers and balancing treatment aggressiveness with value-based care considerations.
Watch
Optimizing Vitiligo Treatment: Safety, Efficacy and Special Population Consideration
November 25th 2024Seemal Desai, M.D., FAAD, discusses how treatment safety and effectiveness must be carefully evaluated through monitoring clinical outcomes and patient-reported measures, with special consideration given to unique challenges in vulnerable populations like children, pregnant women and those with comorbidities, where treatment approaches require careful modification to balance efficacy and safety concerns.
Watch
What the Trump Presidency Will Mean for U.S. Healthcare and Managed Care
November 22nd 2024This webinar on "What the Trump Presidency Will Mean for U.S. Healthcare and Managed Care" includes panelists Lindsay Greenleaf, J.D., MBA; Ryann Hill, M.P.H. and Patrick Cooney, discussing possible changes to healthcare policies and programs under the Trump administration, including the future of the Inflation Reduction and Affordable Care Acts, PBM reform and Medicare Advantage.
Watch
Key Clinical Considerations for Unique Patient Populations
November 22nd 2024Kenan R. Omurtag, M.D., discusses how addressing unique needs of LGBTQ patients involves tailored fertility treatments and legal considerations, while emphasizing the importance of early fertility preservation counseling and expedited procedures for cancer patients, including cryopreservation of eggs, sperm or embryos prior to potentially gonadotoxic treatments.
Watch